qxp 03 07 2018 12:27 Page 43 Governance Directors Remuneration Report The remuneration for the non-executive Directors is Introduction from the Chairman determined within the limits set out in the Companys This report has been prepared in accordance with the Articles of Association.
The present limit is 250,000 in requirements of Section 421 of the Companies Act 2006 and the aggregate per annum.
Enterprise and Regulatory Reform Act 2013.
A non-binding A binding resolution to approve the Directors Remuneration Ordinary Resolution for the approval of this report will be put to Policy was put to shareholders at the Annual General shareholders at the Companys forthcoming Annual General Meeting held in 2017, and was passed with 98.4% of Meeting.
The law requires the Companys Auditors to audit shareholders voting in favour of the Resolution.
The certain of the disclosures provided in this report.
Where aforementioned Directors Remuneration Policy provisions disclosures have been audited, they are indicated as such and apply until the next time that they are put to shareholders for the Auditors audit opinion is included in its report to the renewal of that approval, which must be at intervals of shareholders on pages 46 to 51. not more than three years, or if the Directors Remuneration The Management Engagement & Remuneration Committee Policy is varied.
As approval of this policy was last granted by considers the framework for the remuneration of the shareholders at the Annual General Meeting held in Directors on an annual basis.
It reviews the ongoing September 2017, shareholder approval will again be sought appropriateness of the Directors Remuneration Policy and at the Annual General Meeting to be held in 2020. the individual remuneration of Directors by reference to the activities and particular complexities of the Company and Directors appointment comparison with other companies of a similar structure and None of the Directors has a service contract.
This is in-line with the AIC Code.
their appointment provide that Directors shall retire and be subject to election at the first Annual General Meeting after A non-binding Ordinary Resolution proposing the adoption of their appointment and to re-election annually thereafter.
The the Directors Remuneration Report was put to shareholders terms also provide that a Director may be removed without at the Annual General Meeting of the Company held on notice and that compensation will not be due on leaving office.
14 September 2017, and was passed with 98.5% of the votes cast by shareholders voting in favour of the Resolution.
Directors fees As noted in the Strategic Report, all of the Directors are At the most recent Management Engagement & non-executive and therefore there is no Chief Executive Officer.
Remuneration Committee held on 6 March 2018 it was The Company does not have any employees.
There is therefore agreed that the Directors fees would be, with effect from no Chief Executive Officer or employee information to disclose.
1 April 2018, as follows: The Chairman of the Company, and Humphrey van der Klugt, Directors Remuneration Policy as Chairman of the Audit Committee, receive an annual fee of The Directors Remuneration Policy provides that fees 47,700 and 36,920, respectively.
Dr David Holbrook, as the payable to the Directors should reflect the time spent by the Senior Independent Director will receive an annual fee of Board on the Companys affairs and the responsibilities 32,320, Sarah Bates, Doug McCutcheon and Sven Borho borne by the Directors and should be sufficient to enable each receive an annual fee of 30,130. candidates of high calibre to be recruited.
Directors are remunerated in the form of fees payable monthly in arrears, The Directors, as at the date of this report, all served paid to the Director personally or to a specified third party.
The table overleaf excludes any There are no long-term incentive schemes, share option employers national insurance contributions, if applicable.
schemes, pension arrangements, bonuses, or other benefits The Directors are entitled to be reimbursed for reasonable in place and fees are not specifically related to the Directors expenses incurred by them in connection with the performance, either individually or collectively.
performance of their duties and attendance at Board and General Meetings.
Worldwide Healthcare Trust PLC Annual Report for the year ended 31 March 2018 43 249336 WWH pp40-pp51.
These are reimbursed by the Company and, under HMRC Rules, are subject to tax and National Insurance and therefore are treated as a benefit in kind within this table.
Retired from the Board on 21 September 2016.
Ceased to be a Director on 12 January 2018.
Sven Borho joined the Board on 7 June 2018.
In certain circumstances, under HMRC rules travel and Share price total return other out of pocket expenses reimbursed to the Directors The chart below illustrates the total shareholder return for a may be considered as taxable benefits.
Where expenses are holding in the Companys shares as compared to the classed as taxable under HMRC guidance, they are shown in Benchmark, which the Board has adopted as the key the taxable expenses column of the Directors remuneration measure of the Companys performance.
table along with the associated tax liability.
Total shareholder return for the nine years to No communications have been received from shareholders 31 March 2018 regarding Directors remuneration.
% 520 Sums paid to third parties 480 None of the fees referred to in the above table were paid to 440 400 any third party in respect of the services provided by any of 360 the Directors.
320 280 240 Directors interests in the Companys shares 200 audited 160 Ordinary 120 80 Shares of 25p each Mar-09 Mar-10 Mar-11 Mar-12 Mar-13 Mar-14 Mar-15 Mar-16 Mar-17 Mar-18 31 March 31 March Worldwide Healthcare Share Price total return Benchmark total return 2018 2017 Rebased to 100 as at March 2009 Sir Martin Smith 11,871 11,871 Source: Morningstar, Thomson Reuters and Bloomberg Trustee 2,725 2,725 Sarah Bates 7,200 7,200 Dr David Holbrook 1,094 1,094 Samuel D. Isaly n a 3,600 Humphrey van der Klugt 1,500 1,500 Doug McCutcheon 15,000 15,000 39,390 42,990 Ceased to be a Director on 12 January 2018 Worldwide Healthcare Trust PLC 44 Annual Report for the year ended 31 March 2018 249336 WWH pp40-pp51.
qxp 03 07 2018 12:27 Page 45 Governance Directors Remuneration Report The bar chart below shows the comparative cost of Directors fees compared with the level of dividend distribution and ongoing charges for 2017 and 2018.
Relative cost of Directors remuneration 11000 10000 9000 8000 7000 6000 5000 4000 3000 2000 1000 0 Directors Dividends Ongoing Directors Dividends Ongoing Fees 2018 Charges Fees 2017 Charges 2018 2018 2017 2017 See Glossary beginning on page 72.
Annual statement On behalf of the Board, I confirm that the Directors Remuneration Policy, set out on page 43 of this Annual Report, and Directors Remuneration Report summarise, as applicable, for the year to 31 March 2018: a the major decisions on Directors remuneration: b any substantial changes relating to Directors remuneration made during the year: and c the context in which the changes occurred and decisions have been taken.
Doug McCutcheon Chairman of the Management Engagement & Remuneration Committee 15 June 2018 Worldwide Healthcare Trust PLC Annual Report for the year ended 31 March 2018 45
